Clinical trials: Influenza Type A
- Condition Influenza Type A
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Influenza, Human, Flu, Human
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without immunosuppressive conditions.
- Conditions
- Influenza, Human, Flu, Human, Flu, Avian, Influenza
- Trial name
- NCT02107807
- Testing
- Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine
- Where
- 17 sites in Australia, Germany and 1 more
- Volunteers
- 539 people, healthy volunteers welcome
- Sponsor
- Seqirus
SARS-CoV-2, Influenza A
POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 Ag Ultra test in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and LumiraDx SARS-CoV-2 \& Flu A/B…
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, COVID-19
- Trial name
- PURSUE (NCT05728970)
- Testing
- LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
- Where
- 10 sites in United States
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
Influenza A
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
This is a Phase I double-blind, randomized, placebo-controlled study in 250 healthy adults, 18-49 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03999554
- Testing
- LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD Sing2016 M2SR H3N2 influenza vaccine
- Where
- 4 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
Evaluation of the Safety and Efficacy of a Monoclonal Antibody to Treat Influenza
The purpose of the study is to evaluate the efficacy and safety of MEDI8852 for the treatment of influenza caused by a wild type A/H1N1 challenge strain in healthy, influenza serosusceptible adults.
- Trial name
- NCT03903718
- Testing
- Oseltamivir, MEDI8852
- Volunteers
- healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza A Subtype H5N1 Infection
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe…
- Trial name
- NCT00755703
- Testing
- Pandemic Influenza Vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
H1N1 Influenza Virus, Invasive Solid Tumors
Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors
This is a phase III, randomized, controlled, open label study with two vaccine regimens. The study will assess the relative safety and immunogenicity of vaccine regimens comparing adjuvanted versus non-adjuvanted formulations of…
- Trial name
- NCT01031719
- Testing
- adjuvanted A(H1N1) influenza vaccine, non-adjuvanted A(H1N1) influenza vaccine
- Where
- 3 sites in Brazil
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Chiltern Pesquisa Clinica Ltda
Healthy
Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults
The purpose of this study is to assess the safety, immunogenicity,and tolerability of a H5N1 Vaccine in healthy adults.
- Trial name
- NCT01250795
- Testing
- HAI-05 Influenza Vaccine, Saline
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Fraunhofer, Center for Molecular Biotechnology
Influenza
Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 2009 (swine flu) vaccine in healthy young children
- Trial name
- NCT00996307
- Testing
- MF59-eH1N1_f
- Where
- 29 sites in United States, Mexico
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Immunogenicity and Safety of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine in Infants
The aim of this study is to investigate the immunogenicity and safety of the inactivated split-virion vaccine in infants.
- Trial name
- NCT01494740
- Testing
- split-virion, non-adjuvanted vaccine of 7.5 μg, split-virion, non-adjuvanted H1N1 vaccine of 15 μg, split-virion, non-adjuvanted vaccine of seasonal influenza
- Where
- China
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Tetanus, Diphtheria
Confirmatory Study of BK1310 in Healthy Infants
The purpose of this study is to evaluate immunogenicity of BK1310 for all antigens (anti-PRP, diphtheria toxin, pertussis, tetanus toxin, and polio virus), after 3 times of injection, when compared noninferiority with…
- Conditions
- Tetanus, Diphtheria, Pertussis, Poliomyelitis
- Trial name
- NCT03891758
- Testing
- DPT-IPV-Hib, Hib vaccine, DPT-IPV
- Where
- Japan
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma Corporation
Influenza
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
The primary objective of this study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further…
- Trial name
- NCT00192309
- Testing
- CAIV-T, TIV
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza -Like Illness, Influenza A
Home Testing of Respiratory Illness
The main goal of this research study is to use data from activity trackers (such as Fitbits), lab tests, and surveys to see if activity, sleep, and heart rate data can tell the difference between when someone has a respiratory…
- Conditions
- Influenza -Like Illness, Influenza A, Influenza Type B, Respiratory Viral Infection
- Trial name
- NCT04245800
- Where
- United States
- Volunteers
- 5,233 people, healthy volunteers welcome
- Sponsor
- Evidation Health
Influenza A
Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population
Adopt the design of random, blind method and placebo to parallel control and progressive methods of groups to study and evaluate the safety and immunogenicity of influenza A (H7N9) vaccine (two types, one type with two…
- Trial name
- NCT03196661
- Testing
- Influenza A (H7N9) virus vaccine
- Volunteers
- 588 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Bacterin Co. Ltd.
Influenza
A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza
The objective of this study is to evaluate the safety of the vaccine and the immune response to the vaccine in healthy adult volunteers 65 years of age or older.
- Trial name
- AVX502-003 (NCT00706732)
- Testing
- AVX502
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AlphaVax, Inc.
COVID-19, Influenza A
Clinical Evaluation of the Panbio™ COVID-19/ Flu A&B Rapid Panel
This study is designed as a prospective, multicentric, clinical study to investigate the performance of the Panbio™ COVID-19/ Flu A\&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and…
- Conditions
- COVID-19, Influenza A, Influenza Type B
- Trial name
- NCT05163730
- Testing
- COVID-19/ Flu A&B Rapid Panel
- Where
- United States
- Volunteers
- 2,472 people, healthy volunteers welcome
- Sponsor
- Abbott Rapid Diagnostics Jena GmbH
Haemophilus Influenzae, Haemophilus Influenzae Type a
Phase 2 Trial of a Haemophilus Influenzae Serotype a (Hia) Glycoconjugate Vaccine
This study is testing a vaccine designed to protect against Haemophilus influenzae type a (Hia), a bacterium that can cause serious infections.This is a phase 2 trial.
- Trial name
- NCT07743008
- Testing
- Haemophilus influenzae serotype a vaccine candidate
- Where
- 2 sites in Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- InventVacc Biologicals Inc.
Healthy
A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine,(CAIV-T) in Healthy Infants
Trial to compare the safety and tolerability of one and two doses of influenza virus vaccine.
- Trial name
- NCT00192348
- Testing
- CAIV-T
- Where
- Finland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Novartis Pandemic Influenza A (H1N1) Vaccine(s) Observational Comparative Safety Study
The primary objective of this observational, comparative safety study is to evaluate the safety of the Novartis Pandemic Influenza A (H1N1) vaccine in pregnant women and their off spring, followed for up to 3 months of age as…
- Trial name
- NCT01037829
- Testing
- Non-intervention observational study
- Where
- 17 sites in Argentina, Italy and 1 more
- Volunteers
- 4,529 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza A
Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)
This study has been designed to evaluate the safety and immunogenicity of two different formulations of FP-01.1 as well as build on the data set from the first in human study FP-01.1_CS_01.
- Trial name
- NCT01677676
- Testing
- FP-01.1, FP-01.1-Adjuvant
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Immune Targeting Systems Ltd
Influenza
Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza
To demonstrate that the efficacy over a defined surveillance period against culture-confirmed influenza-illness caused by community-acquired subtypes antigenically similar to those contained in the vaccine, in adults aged at…
- Trial name
- FluMist (NCT00192413)
- Testing
- Cold-adapted influenza vaccine trivalent (CAIV-T), Trivalent Inactivated Vaccine (TIV)
- Where
- 4 sites in South Africa
- Volunteers
- 3,009 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC